New Method for the Early Diagnosis of Disease
Entelechon GmbH was founded in 1999 in Regensburg and produces synthetic genes and vectors per contract. The company has developed, in cooperation with the English scientists of the University of Liverpool and Manchester, a technology that makes the early recognition of disease possible. Whilst treatment often is first able to be commenced with the appearance of the initial symptoms, the cause of the disease has often already arisen at a far earlier point in time – at a molecular level in the patient’s cells. Generally an alteration of essential biological processes marks the onset of diseases such as multiple sclerosis or Parkinson’s disease. These changes in the organism can now be recognised early on with the new diagnostic methodology. With the identification of so-called 'biomarkers', the relative quantities of substances produced naturally in the body, which change at cellular level when ill, can be measured with a sample taken from the patient. Regensburg now has the goal of building up a production platform, and developing and bringing these initial diagnostic methods onto the market in cooperation with pharmaceutical companies, researchers and doctors.
For more information see: